RJ Hamster
(Nasdaq: OKYO) Could Draw Buzz From Key Breaking News…
Any content you receive is for information purposes only. Always conduct your own research.
(Nasdaq: OKYO) Could Draw Buzz From Key Breaking News Today (Bullish Technicals – Low Float)
*Click Here To Get Our Alerts Faster Via SMS*
January 23rd
Greetings Readers,
OKYO Pharma Limited (Nasdaq: OKYO)may start gaining some serious attention Friday following breaking news.
Check it out:
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has authorized a single-patient expanded access (compassionate use) Investigational New Drug (IND) applicationsubmitted by Pedram Hamrah, MD, at the University of South Florida, for the use of urcosimod (0.05%) in a patient with neuropathic corneal pain.
Under the FDA-authorized expanded access (IND 176297), urcosimod is being provided by OKYO Pharma for use in a patient with severe neuropathic corneal pain who has limited therapeutic options and no FDA-approved treatments available.
“We are grateful that this FDA authorization allows us to explore the potential of urcosimod in a patient with severe neuropathic corneal pain through a physician-sponsored expanded access IND,” said Pedram Hamrah, MD, Vice Chair of Academic Medicine, Department of Ophthalmology, University of South Florida. “Neuropathic corneal pain is a complex condition involving both immune-mediated inflammation and dysfunctional nerve signaling. Urcosimod’s proposed dual mechanism of action, potentially targeting both pathways provides a strong scientific rationale for investigation in this setting.”
“Supporting physician-sponsored expanded access to urcosimod under compassionate use in the U.S. highlights the pressing global need for innovative therapies to specifically address neuropathic corneal pain,” said Robert J. Dempsey, Chief Executive Officer, OKYO Pharma. “This also reflects the potential new hope for patients battling this debilitating painful condition with no FDA approved treatment available today.”
As previously communicated, urcosimod was granted the first IND to treat patients with NCP and was awarded fast track designation by the Food and Drug Administration (FDA). The company expects to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP this year.
Remember, OKYO has a low float.
With fewer than 23Mn shares in its float, there could be strong potential for heightened volatility on a daily basis.
Also, don’t forget that OKYO has several triggered technical indicators over at Barchart.
Take a second to review my initial (Nasdaq: OKYO) report below and consider this profile for your watchlist.
—–
A clinical-stage biopharma company is tackling one of medicine’s most persistent challenges—developing treatments that address both the symptoms and underlying causes of eye and inflammatory diseases.
With a strong scientific foundation and an ambitious clinical roadmap, this organization is translating breakthrough discoveries into targeted therapies designed to improve patients’ daily lives.
Its work bridges academic innovation and real-world medical need, setting a pace that few in the space are matching.
This could be one of those rare opp’s where meaningful science meets significant global impact.
And with multiple bullish technicals, strong analyst targets, a key inside share purchase, and relatively low float, this under-the-radar Nasdaq idea tops our watchlist:
OKYO Pharma Limited (Nasdaq: OKYO)
OKYO Pharma Ltd. is a biopharmaceutical company dedicated to developing an innovative treatment for neuropathic corneal pain and dry eye disease.
The company aims to provide targeted therapy that not only alleviates pain but also controls inflammation, while enhancing ocular residence time for more effective, lasting relief.
And based on 5 potential catalysts, (Nasdaq: OKYO) has risen to the top spot on my watchlist. Check them out:
No. 1 – At Least 3 Analyst Targets Are Suggesting OKYO To Have Triple-Digit Upside Potential!
No. 2 – A Multitude Of Bullish Technical Indicators Surround OKYO Across 3 Separate Terms.
No. 3 – An Insider Purchase Could Raise Eyebrows That Company Confidence Is Brimming.
No. 4 – Promising Data Shows Urcosimod May Help Restore Corneal Nerve Structure In Patients With NCP.
No. 5 – With A Relatively Low Float, Volatility Potential Could Be Heightened (Daily).
But more on those in a second…
Neuropathic Corneal Pain (NCP)
NCP is a severe, chronic, and debilitating disease for which there are no approved commercial treatments currently available.
Current treatments are limited to short term NSAIDs, steroids, and opioids in severe cases. Side effects and the risk of addiction to o-p-ioids is a serious concern.
Often underdiagnosed, as the symptoms can overlap with other eye conditions, and treatment can be difficult to manage effectively.
ChemR23 receptor on leukocytes targeted by urcosimod is also expressed on neurons and glial cells in the dorsal root ganglion and spinal cord.
Topical administration of urcosimod was effective in suppressing corneal pain in a ciliary nerve ligation mouse model of NCP similar to that of gabapentin, a commonly used oral drug for neuropathic pain, given by intraperitoneal injection.
The pain-relieving potential of urcosimod is very important because a considerable number of dry eye patients with chronic inflammation also suffer from ocular pain.
Urcosimod (formerly called OK-101) Drug Candidate
Urcosimod is a novel class of chemerin (ChemR23 or CMKLR1) receptor agonist that produces an anti-inflammatory and reduction in neuropathic pain.
The chemerin receptor is a G protein-coupled receptor (GPCR) found on select immune, epithelial, and dorsal root ganglion/spinal cord neuronal cells.
Activation of chemerin receptor has been shown to modulate the resolution of inflammation and neuropathic pain.
Urcosimod can potentially benefit patients suffering from ocular pain and ocular inflammation.
Dry Eye
Dry Eye affects over 35% of the population aged 50+, with women representing approximately two-thirds of those affected.
Worldwide, ~700Mn patients suffer from dry eye disease.
Several side effects and modest efficacy of currently available drugs demand new therapies to treat dry eye disease.
Huge potential for new drugs for a $5Bn dry eye market.
—–
Phase 2 NCP Clinical Trial Demonstrated Promising Drug Effect
Phase 2, Randomized, Double Masked, Placebo-Controlled Study Assessing Safety and Efficacy for Urcosimod in Subjects with NCP
STUDY RESULTS
- After 12 weeks of treatment, 75% of per-protocol patients receiving urcosimod (0.05%) showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment.
- The urcosimod (0.05%) group showed a mean pain score improvement of 5.5 points on a 10-point VAS, compared with a mean improvement of 2.75 points for placebo.
- Urcosimod (0.05%) demonstrated a marked reduction in pain scores as early as Week 4, with sustained efficacy maintained throughout the trial.
- Notably, all these responders entered the study with moderate to severe NCP pain scores despite prior use of maximum medical therapy.
- No serious adverse events were reported among the 18 patients throughout the trial.
Pipeline
Sources: OKYO Website. OKYO Presentation.
—–
And mentioned above, (Nasdaq: OKYO) has several potential catalysts to consider focusing on. Check them out:
No. 1 OKYO Potential Catalyst – At Least 3 Analyst Targets Are Suggesting OKYO To Have Triple-Digit Upside Potential!
That’s right. At least different analyst targets are suggesting OKYO to have triple-digit upside potential from Thursday’s closing valuation.
More specifically:
H.C. Wainwright & Co.’s $7 target suggests 175+% potential upside.
Lucid Capital Markets’ $13 target suggests over 400% potential upside.
And B. Riley Securities $5 target suggests more than 100% potential upside
Take a moment to click the picture aboveand get a look at all 3 reports.
—–
No. 2 OKYO Potential Catalyst – A Multitude Of Bullish Technical Indicators Surround OKYO Across 3 Separate Terms.
On Thursday at 4:00PM EST, Barchart was reporting several triggered technical indicators indicators across the short, medium, and long term for OKYO.
Here’s their list (as of 4:00PM EST Thursday):
Short Term Indicators
- 20 Day Moving Average
- 20 – 50 Day MA Crossover
- 20 – 100 Day MA Crossover
- 20 – 200 Day MA Crossover
Medium Term Indicators
- 50 Day Moving Average
Long Term Indicators
- 100 Day Moving Average
- 200 Day Moving Average
- 100 – Day MA Crossover
Make sure to watch these technical indicators closely moving forward.
—–
No. 3 OKYO Potential Catalyst – An Insider Purchase Could Raise Eyebrows That Company Confidence Is Brimming.
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 24,551 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,516,297 shares.
—–
No. 4 OKYO Potential Catalyst – Promising Data Shows Urcosimod May Help Restore Corneal Nerve Structure In Patients With NCP.
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
- Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo group
- These findings suggest that urcosimod may have a positive impact on corneal nerve health in patients with neuropathic corneal pain
- Corneal nerve imaging data from the Phase 2 NCP trial were analyzed using in vivo confocal microscopy
LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce new analyses of corneal images from the recently completed placebo-controlled, randomized, double-masked, Phase 2 clinical trial of urcosimod in neuropathic corneal pain (NCP). Patients treated with 0.05% urcosimod demonstrated not only a positive reduction in neuropathic corneal pain, but also favorable changes in corneal nerve structure which were not observed in the placebo group.
…
“These results provide early evidence that urcosimod may help restore corneal nerve structure in patients suffering from neuropathic corneal pain,” said Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma. “While exploratory, these findings reinforce our long-standing belief that targeting the chemerin receptor pathway may open a new therapeutic avenue for patients with neuropathic corneal pain. We are encouraged by the biological activity observed and believe they provide an important foundation for the continued development of urcosimod.”
—–
No. 5 OKYO Potential Catalyst – With A Relatively Low Float, Volatility Potential Could Be Heightened (Daily).
According to info from the Yahoo website, OKYO has a relatively low float.
The website reports this profile to have roughly 22.47Mn shares in its float.
Why is that important? It’s important on one crucial level. Volatility potential.
If the company provides positive news at the beginning of 2026, could it help provide a breakout spark when paired with this volatility potential?
—–
(Nasdaq: OKYO) Recap – 5 Potential Breakout Catalysts Lead The Way!
No. 1 – At Least 3 Analyst Targets Are Suggesting OKYO To Have Triple-Digit Upside Potential!
No. 2 – A Multitude Of Bullish Technical Indicators Surround OKYO Across 3 Separate Terms.
No. 3 – An Insider Purchase Could Raise Eyebrows That Company Confidence Is Brimming.
No. 4 – Promising Data Shows Urcosimod May Help Restore Corneal Nerve Structure In Patients With NCP.
No. 5 – With A Relatively Low Float, Volatility Potential Could Be Heightened (Daily).
—–
Coverage is now officially kicked-off on OKYO Pharma Limited (Nasdaq: OKYO).
Be ready for updates coming your way soon.
Sincerely,
Kai Parker
StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 01/22/2026 and ending on 01/23/2026 to publicly disseminate information about (OKYO:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid thirty five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (OKYO:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/okyo-7qjxm/#details
SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US
Unsubscribe | Update Profile | Constant Contact Data Notice
